ADVANCES IN LUNG CANCER: THE VALUE OF COMMUNITY-BASED RESEARCH
PHOENIX (Nov. 20, 2013)—Lung cancer is the number-one form of cancer that kills both men and women in the United States. In 2013, more than 228,190 Americans will be diagnosed with the disease—an increase of more than 7,000 from 2012, and approximately 159,480 people will die.
In August of 2005, the National Cancer Institute (NCI) announced an integrated effort to eliminate the suffering and death due to lung cancer by 2015. As part of this integrated implementation plan, three critical strategies are being targeted:
- Reducing the risk for lung cancer by achieving more effective tobacco control.
- Improving the likelihood of a cure through earlier detection and treatment of lung cancer and pre-cancer.
- Introduction of novel targeted therapies through cohesive partnerships with ongoing or planned biology initiatives.
Arizona Oncology plays a major role in the battle against lung cancer by providing easy access to a full range of advanced cancer care services for patients fighting lung cancer. Our medical and radiation oncologists and their staffs provide chemotherapy, injections, infusion services, radiation therapy and diagnostic imaging services in a setting that allows patients to remain close to their homes and their support network of family and friends. As a result, patients access the best possible treatment with the least amount of disruption to their daily lives.
Through its affiliation with US Oncology, one of the nation’s largest healthcare services networks dedicated exclusively to cancer treatment and research, Arizona Oncology also brings opportunities to participate in the ongoing clinical research and development of the newest promising cancer therapies to patients in Arizona.
“Clinical trial availability is critical for cancer researchers and patients alike,” said Arizona Oncology Medical Oncologist Mahesh Seetharam. “Because of the vast number of trials under way at any one time, there is a great need for patients who meet participation criteria. Community-based oncology centers, such as ours, play a major role in identifying patients who qualify, while also extending the reach of promising investigational therapies to more patients.”
Currently Arizona Oncology is participating in five lung cancer clinical trials. More can be found about them by visiting http://arizonaoncology.com//clinical-trials/category/lung/
About Arizona Oncology
Arizona Oncology is united in healing with US Oncology, a division of McKesson Corporation and a leading integrated oncology company uniting one of the nation’s largest community-based cancer treatment and research networks to accelerate the availability and use of evidence-based medicine and shared best practices. As an affiliate of the United Network of US Oncology, Arizona Oncology is united with more than 1,100 physicians and 10,000 cancer professionals nationwide. Through the US Oncology Research Network, Arizona Oncology in clinical trials and has helped to develop 43 FDA approved cancer therapies. For more information, visit www.usoncology.com.